This systematic review and meta-analysis presents 13 randomized controlled trials that analyzed pain and safety outcomes for patients treated with tanezumab for osteoarthritis of the hip or knee. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale was used at baseline and follow-up and adverse events (AEs), including treatment-related and serious AEs, were reported at follow-up. For 11,388 patients, LS means change-from-baseline for the WOMAC Pain subscale was -9.4 [-10.1, -8.8] across all tanezumab doses, -3.6 [-3.9. -3.2] for placebo, -2.7 [-2.7, -2.6] for naproxen, -2.2 [-2.3, -2,1] for combination therapy, -2.6 [-2.6, -2.6] for oxycodone, -2.4 for non-steroidal anti-inflammatory drugs (NSAIDs), and -1.7 [-1.7, -1.6] for placebo+NSAID. For safety outcomes, AEs were observed among all treatments including 63.3% for oxycodone, 60.3% for NSAIDs, 59.0% for combination therapy, 57.8% for tanezumab, 52.0% for placebo, 50.5% for naproxen, and 34.9% for placebo+NSAID across 6,900 patients. For 973 patients, treatment-related AEs were observed in 41.1%, 17.3%, 15.9%, and 13.5% of the oxycodone, tanezumab, NSIAD, and placebo treatments, respectively. For 601 patients, serious AEs were observed in all treatments including 9.1% 5.3%, 4.6%, 3.8%, 2.8%, 2.5% and 2.4% in the combination therapy, placebo+NSAID, NSAID, tanezumab, placebo, oxycodone, and naproxen groups, respectively.